Galectin-3 mediated risk of inflammation in stable schizophrenia, with only possible secondary consequences for cognition

doi:10.5498/wjp.v12.i9.1183

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 9

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4106)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-1) series.

Item

Count

PDF

241

WORD

HTML

1688

Figures (1-2)

161

Tables (1-1)

179

Sum=2328

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

190

Download

588

Sum=778

Publishing Process of This Article

Item

Count

Browse

299

Download

701

Sum=1000

Sep 19, 2022 (publication date) through Nov 29, 2024

Times Cited of This Article

Times Cited (2)

Journal Information of This Article

Publication Name

World Journal of Psychiatry

ISSN

2220-3206

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Control Study

World J Psychiatry. Sep 19, 2022; 12(9): 1183-1193
Published online Sep 19, 2022. doi: 10.5498/wjp.v12.i9.1183

Full Size Figure Download Figure

Figure 1 Transforming growth factor-beta and galectin-3 levels impact the illness. A: Lower transforming growth factor-beta (TGF-β) levels (272.09 ± 101.59 vs 360.41 ± 45.13 pg/mL, P = 0.003) were measured in patients; B: These parameters of serum concentrations of galectin-3 and TGF-β both had an impact on disease presentation. TGF-β: Transforming growth factor-beta; IL: Interleukin; Gal-3: Galectin-3.

Citation: Minic Janicijevic S, Jovanovic IP, Gajovic NM, Jurisevic MM, Debnath M, Arsenijevic NN, Borovcanin MM. Galectin-3 mediated risk of inflammation in stable schizophrenia, with only possible secondary consequences for cognition. World J Psychiatry 2022; 12(9): 1183-1193
URL: https://www.wjgnet.com/2220-3206/full/v12/i9/1183.htm
DOI: https://dx.doi.org/10.5498/wjp.v12.i9.1183